Form 4: Adverum Director's Options Cancelled Post-Eli Lilly Merger

Adverum Biotechnologies director C. David Nicholson's stock options were cancelled following the company's acquisition by Eli Lilly and Company, effective December 9, 2025.

Summary

• Adverum Biotechnologies, Inc. was acquired by Eli Lilly and Company through its direct wholly-owned subsidiary, Flying Tigers Acquisition Corporation.
• The merger became effective on December 9, 2025, resulting in Adverum continuing as a wholly-owned subsidiary of Eli Lilly.
• Tendering stockholders of Adverum received $3.56 per share in cash and one non-tradable contingent value right (CVR), which represents the contractual right to receive up to two contingent cash payments totaling up to an aggregate of $8.91 per CVR.
• C. David Nicholson, a director of Adverum, had his stock options cancelled as a result of the merger.
• Stock options with an exercise price equal to or greater than the $3.56 cash consideration were fully vested prior to the merger and then cancelled for no consideration.
• Stock options with an exercise price less than the $3.56 cash consideration were cancelled in exchange for cash (equal to the difference between the cash consideration and the exercise price) and one CVR for each share underlying the option.

Sentiment

Score: 7

Explanation: The merger completion provides liquidity and potential upside via CVRs for shareholders, representing a definitive outcome for the company. However, the cancellation of out-of-the-money options without value is a negative for those specific option holders.

Positives

• Adverum shareholders who tendered their shares received immediate liquidity of $3.56 per share in cash.
• Shareholders and holders of 'Cash-Out Stock Options' received contingent value rights (CVRs) offering potential future payments of up to $8.91 per CVR upon achievement of specified milestones.
• Holders of 'Cash-Out Stock Options' received cash consideration for the in-the-money portion of their options.

Negatives

• Stock options with an exercise price equal to or greater than the $3.56 cash consideration ('Out-of-the-Money Options') were cancelled for no consideration.

Risks

• The contingent value rights (CVRs) are non-tradable, limiting liquidity for these rights.
• The realization of the full potential value of up to $8.91 per CVR is contingent upon the achievement of specified milestones, which may not occur.

Future Outlook

Adverum Biotechnologies, Inc. is now a wholly-owned subsidiary of Eli Lilly and Company, ceasing to operate as an independent publicly traded entity. The future financial performance and strategic direction of Adverum will be integrated into Eli Lilly's operations. The contingent value rights (CVRs) represent the only remaining future financial interest for former Adverum shareholders, dependent on the achievement of specified milestones.

Industry Context

This transaction exemplifies a common trend in the biotechnology sector where larger pharmaceutical companies acquire smaller, often clinical-stage, biotech firms to bolster their pipeline or gain access to specific technologies. The use of contingent value rights (CVRs) is a frequent mechanism in such acquisitions, allowing the acquirer to share future development risks and rewards with the target company's former shareholders, particularly when the acquired assets have significant future value potential but also inherent development uncertainties.

Comparison to Industry Standards

• The use of a cash component ($3.56 per share) combined with contingent value rights (CVRs) for potential future payments (up to $8.91 per CVR) is a common acquisition structure in the biotechnology and pharmaceutical industries.
• This structure is often employed in deals involving clinical-stage or early commercial-stage assets, allowing the acquirer (Eli Lilly) to mitigate risk while providing target shareholders (Adverum) with potential upside tied to future development or commercial milestones.
• Specific comparable companies, projects, or results are not detailed in this filing to allow for a direct quantitative comparison of the deal terms.

Related Party Transactions

• The transaction involves C. David Nicholson, a director of Adverum Biotechnologies, and the acquisition of Adverum by Eli Lilly and Company, impacting Nicholson's beneficial ownership of Adverum securities.

Stakeholder Impact

• Shareholders: Received cash and CVRs, providing liquidity and potential future payments based on milestone achievement.
• Option Holders: Those with in-the-money options received cash and CVRs; those with out-of-the-money options had them cancelled for no consideration.
• Company (Adverum): Ceased to be an independent public entity, becoming a wholly-owned subsidiary of Eli Lilly, implying significant changes to its operational and strategic autonomy.

Next Steps

• Achievement of specified milestones for the contingent value rights (CVRs) to trigger potential future cash payments.

Key Dates

Keywords

Adverum Biotechnologies, ADVM, Eli Lilly, Merger, Acquisition, Form 4, Stock Options, CVR, Contingent Value Rights, Tender Offer, Insider Transaction